Ashling Wahner

The FDA issued a CRL to RP1 plus nivolumab for the management of advanced melanoma after progression on an anti–PD-1–containing regimen.

An NDA seeking the approval of TLX101-Px for characterizing treatment-related changes in recurrent or progressive glioma has been accepted by the FDA.

Manish Patel, DO, discusses early evidence suggesting that AR inhibition may enhance the efficacy of immunotherapy in salivary gland cancer.

ASCO has published updates to the clinical practice guidelines for the use of systemic therapy across subsets of patients with thyroid cancer.

A BLA has been accepted in China seeking the approval of second-line trastuzumab pamirtecan for unresectable or metastatic HER2-positive breast cancer.

Frontline tislelizumab/chemotherapy yielded sustained PFS outcomes and a meaningful OS improvement vs placebo/chemotherapy in recurrent or metastatic NPC.

IMPT generated similar physical QOL scores, local disease control, gastronomy tube dependence, and OS vs IMRT in oropharyngeal squamous cell carcinoma.

Catch up on insights into the global development of breast cancer therapies that are making waves around the world.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

Neoadjuvant THP demonstrated noninferiority compared with standard TCbHP in patients with stage II or III HER2-positive breast cancer.

Read our recap of top phase 1 and 2 breast cancer data announcements and highlights that may influence further clinical research and developments.

The FDA has granted traditional approval to brexucabtagene autoleucel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Read a refresh of the top FDA news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

Neoadjuvant anbenitamab plus albumin-bound docetaxel yielded a significant tpCR benefit vs standard therapy in HER2-positive early breast cancer.

Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.

The EMA's CHMP recommends marketing authorization for tarlatamab monotherapy for ES-SCLC following relapse during or after platinum-based chemotherapy.

Neoadjuvant T-DXd followed by THP has received conditional approval in China for the treatment of patients with HER2-positive stage II/III breast cancer.

The PI3Kα inhibitor risovalisib has been approved in Japan for PIK3CA-mutated ovarian clear cell carcinoma after progression on chemotherapy.

Oncology experts ask and answer multidisciplinary questions based on presentations from the 43rd Annual Miami Breast Cancer Conference.

Megan Kruse, MD, discusses the use of imaging modalities in breast cancer management and emphasizes the role of FES-PET/CT in identifying ER presence.

The FDA approved relacorilant plus nab-paclitaxel for previously treated platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer.

Marla D. Lipsyc-Sharf, MD, discusses the evolving role of MRD ctDNA testing in breast cancer management and aiding in early detection of disease recurrence.

The FDA has approved nivolumab plus AVD for adult and pediatric patients with previously untreated stage III or IV classical Hodgkin lymphoma.

Sarah Sammons, MD, discusses how pumitamig’s dual-protein targets position it as a unique agent within the TNBC treatment arena.

First-line sacituzumab govitecan plus pembrolizumab generated efficacy and safety improvements vs chemotherapy plus pembrolizumab in PD-L1–positive mTNBC.

First-line ficerafusp alfa at 2000 mg every 2 weeks plus pembrolizumab was deemed safe and effective in recurrent or metastatic HPV-negative HNSCC.

The NCCN guidelines endorse frontline sacituzumab govitecan alone for PD-L1–negative mTNBC and in combination with pembrolizumab for PD-L1–positive mTNBC.

PMD-026 inhibits RSK to block tumor growth signals and ER activity, a potential strategy to overcome CDK4/6 inhibitor resistance in breast cancer.